Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

Andrew D. Norden, Keith L. Ligon, Samantha N. Hammond, Alona Muzikansky, David A. Reardon, Thomas J. Kaley, Tracy T. Batchelor, Scott R. Plotkin, Jeffrey J. Raizer, Eric T. Wong, Jan Drappatz, Glenn J. Lesser, Sam Haidar, Rameen Beroukhim, Eudocia Q. Lee, Lisa Doherty, Debra Lafrankie, Sarah C. Gaffey, Mary Gerard, Katrina H. SmithChristine McCluskey, Surasak Phuphanich, Patrick Y. Wen*

*Corresponding author for this work

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Objective: A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has proven effective. Methods: Pasireotide LAR is a long-acting somatostatin analog that may inhibit meningioma growth. This was a phase II trial in patients with histologically confirmed recurrent or progressive meningioma designed to evaluate whether pasireotide LAR prolongs progression-free survival at 6 months (PFS6). Patients were stratified by histology (atypical [World Health Organization grade 2] and malignant [grade 3] meningiomas in cohort A and benign [grade 3] in cohort B). Results: Eighteen patients were accrued in cohort A and 16 in cohort B. Cohort A had median age 59 years, median Karnofsky performance status 80, 17 (94%) had previous radiation therapy, and 11 (61%) showed high octreotide uptake. Cohort B had median age 52 years, median Karnofsky performance status 90, 11 (69%) had previous radiation therapy, and 12 (75%) showed high octreotide uptake. There were no radiographic responses to pasireotide LAR therapy in either cohort. Twelve patients (67%) in cohort A and 13 (81%) in cohort B achieved stable disease. In cohort A, PFS6 was 17%and median PFS 15 weeks (95%confidence interval: 8-20). In cohort B, PFS6 was 50% and median PFS 26 weeks (12-43). Treatment was well tolerated. Octreotide uptake and insulin-like growth factor-1 levels did not predict outcome. Expression of somatostatin receptor 3 predicted favorable PFS and overall survival. Conclusions: Pasireotide LAR has limited activity in recurrent meningiomas. The finding that somatostatin receptor 3 is associated with favorable outcomes warrants further investigation. Classification of evidence: This study provides Class IV evidence that in patients with recurrent or progressive meningioma, pasireotide LAR does not significantly increase the proportion of patients with PFS at 6 months.

Original languageEnglish (US)
Pages (from-to)280-286
Number of pages7
JournalNeurology
Volume84
Issue number3
DOIs
StatePublished - Jan 1 2015

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma'. Together they form a unique fingerprint.

  • Cite this

    Norden, A. D., Ligon, K. L., Hammond, S. N., Muzikansky, A., Reardon, D. A., Kaley, T. J., Batchelor, T. T., Plotkin, S. R., Raizer, J. J., Wong, E. T., Drappatz, J., Lesser, G. J., Haidar, S., Beroukhim, R., Lee, E. Q., Doherty, L., Lafrankie, D., Gaffey, S. C., Gerard, M., ... Wen, P. Y. (2015). Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology, 84(3), 280-286. https://doi.org/10.1212/WNL.0000000000001153